Find participating medical centers and current study status in each of them
-
Home
-
Clinical Study Finder
- Clinical Study Details
A study to look at the long-term safety of a medicine, efmarodocokin alfa, in people with ulcerative colitis
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
Autoimmune Disorder Crohn's Disease Inflammatory Bowel Disease (IBD) Ulcerative Colitis
Basic Details
Study Summary
This clinical trial was done to study a new medicine called, “efmarodocokin alfa”, for the treatment of patients with ulcerative colitis. This was a Phase 2 open-label extension study to find out the long-term safety and tolerability of efmarodocokin alfa in patients with moderate to severe ulcerative colitis. It was carried out at 66 study centers in fourteen countries.
Eligibility Criteria
Inclusion Criteria for Study Entry:
- Prior enrollment in Study GA29469 or Study GA39925 and meeting protocol defined entry criteria
Inclusion Criteria for Study Entry and Study Re-Entry:
- Ability to comply with requirements of the study, in the investigator's judgment
- For women and men: use of highly effective contraception as defined by the protocol.
Exclusion Criteria for Study Entry:
- Withdrawal of consent from parent study
- Discontinuation of study drug as required by the parent study protocol
- Discontinuation of study drug and withdrawal from Study GA29469 prior to Day 85 or from Study GA39925 prior to Week 8
- Noncompliance in the parent study, specifically defined as missing scheduled visits or non-adherence with background medications and concomitant medications
Exclusion Criteria for Study Entry and Study Re-Entry:
- Pregnant or breastfeeding, or intending to become pregnant during the study or within 8 weeks after the final dose of study drug or within 18 weeks after the final dose of study drug from GA39925, whichever is longer
- Any new malignancy, significant uncontrolled comorbidity, such as cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders, or signs or symptoms of infection judged by the investigator to be clinically significant since enrolling in the parent study
- Use of prohibited therapies as defined in the parent study
- Abnormal laboratory values, as defined in the protocol, recorded at the last visit in the parent study
Exclusion Criterion for Study Re-Entry:
- Use of prohibited concomitant therapy since enrolling in the extension study
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
Explore related studies
Study results
LPS GA40209 SERENGETI Final Results April 2023 Bulgaria Bulgarian
(PDF, 0.2 MB)
LPS GA40209 SERENGETI Final Results April 2023 English
(PDF, 0.2 MB)
LPS GA40209 SERENGETI Final Results April 2023 Georgia Georgian
(PDF, 0.2 MB)
LPS GA40209 SERENGETI Final Results April 2023 Germany German
(PDF, 0.2 MB)
LPS GA40209 SERENGETI Final Results April 2023 Greece Greek
(PDF, 0.2 MB)
LPS GA40209 SERENGETI Final Results April 2023 Italy Italian
(PDF, 0.2 MB)
LPS GA40209 SERENGETI Final Results April 2023 Moldova Romanian
(PDF, 0.2 MB)
LPS GA40209 SERENGETI Final Results April 2023 Poland Polish
(PDF, 0.2 MB)
LPS GA40209 SERENGETI Final Results April 2023 Russia Russian
(PDF, 0.2 MB)
LPS GA40209 SERENGETI Final Results April 2023 Serbia Serbian
(PDF, 0.2 MB)
LPS GA40209 SERENGETI Final Results April 2023 Spanish Spain
(PDF, 0.2 MB)
LPS GA40209 SERENGETI Final Results April 2023 Spanish USA
(PDF, 0.1 MB)
LPS GA40209 SERENGETI Final Results April 2023 Ukraine Ukrainian
(PDF, 0.2 MB)
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com